Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.78 USD | +0.39% | +3.42% | -28.35% |
06/03 | Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating | MT |
29/02 | UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.35% | 619M | C- | ||
-19.14% | 8.22B | B+ | ||
+47.71% | 3.73B | C+ | ||
-7.71% | 2.46B | - | ||
-38.71% | 2.46B | B- | ||
-8.84% | 2.36B | B- | ||
-13.72% | 1.78B | C- | ||
-18.68% | 1.52B | A- | ||
-40.78% | 1.21B | C+ | ||
+8.32% | 1.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FLGT Stock
- Ratings Fulgent Genetics, Inc.